Back
ESC Professional Premium Access

Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis of cohort studies

Session: Coronary artery disease - Pharmacotherapy 3
Topic: Pharmacotherapy
Speaker: Mr S. Soulaidopoulos (Athens, GR)
Event: ESC Congress 2022

Congress Presentation

About the speaker

Mr Stergios Soulaidopoulos

Hippokration General Hospital, Athens (Greece)
0 follower

6 more presentations in this session

Effect of exercise-based cardiac rehabilitation on the ischemic threshold in patients with high-risk ischemic heart disease

Speaker: Doctor J. Lara Vargas (Mexico, MX)

Access
Abstract
Slides
Thumbnail

Impact of different antiplatelet therapy cessation modes on outcomes in patients treated with ticagrelor with or without aspirin after PCI: the twilight-antiplatelet cessation study

Speaker: Doctor A. Spirito (New York, US)

Access
Abstract
Slides
Thumbnail

Low dose rivaroxaban therapy in aspirin allergic patients undergoing percutaneous coronary intervention

Speaker: Doctor S. Manjooran (London, GB)

Access
Abstract
Slides
Thumbnail

Lipoprotein(a), cardiovascular events, and benefit of P2Y12 inhibition: insights from the PEGASUS-TIMI 54 trial

Speaker: Doctor S. Patel (Boston, US)

Access
Abstract
Slides
Thumbnail

Thrombin generation and endothelial progenitor cell function among patients with acute myocardial infarction treated with prasugrel versus ticagrelor

Speaker: Doctor M. Wiessman (Petah Tikva, IL)

Access
Abstract
Slides
Thumbnail

Access the full session

Coronary artery disease - Pharmacotherapy 3

Speakers: Mr S. Soulaidopoulos, Doctor J. Lara Vargas, Doctor A. Spirito, Doctor S. Manjooran, Doctor S. Patel...
Access
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb